(Corrected figure) Increased PTPROt expression in human fatty liver macrophages is associated with the severity of nonalcoholic fatty liver disease (NAFLD). A. Fluorescence microscopy of PTPROt and CD68 in the section from the liver tissues of individuals without NAFLD (no steatosis; n = 24), with simple steatosis (n = 32), or with NASH (n = 54), described in Table S3. (Green: PTPROt; Red: CD68; Blue: DAPI; Bar = 100 μm). B. Statistical analysis of PTPROt signal points in Figure 6A. C. PTPROt mRNA levels in liver macrophages isolated from the livers of individuals without NAFLD (no steatosis; n = 24), with simple steatosis (n = 32), or with NASH (n = 54), described in Table S3. D. Pearson's comparison analyses of the correlation between PTPROt mRNA levels described in Fig 1.C and NASH (r = 0.9274), BMI (r = 0.6307), serum ALT concentrations (r = 0.8391), serum AST concentrations (r = 0.8739), serum TG concentrations (r = 0.7875) and serum γ-GT concentrations (r = 0.8624) (n = 110). P < 0.0001 for all of these correlations by Spearman's rank correlation coefficient analysis. Abbreviations: ALT: Alanine aminotransferase; AST: Alanine aminotransferase; BMI: body mass index; DAPI: 4',6-diamidino-2-phenylindole; HDL: High Density Lipoprotein; LDL: Low Density Lipoprotein; NASH: nonalcoholic steatohepatitis; PTPROt: Protein tyrosine phosphatase receptor type O truncated isoform; qRT-PCR: quantitative real-time PCR; TG: Triglyceride; γ-GT: γ-glutamyl transpeptidase.